Replies to post #35418 on Rebus Holdings Inc (RBSH)

[Big Tom7]

I don't know how a company that has a product that went through clinical trials is a scam. This seems legit. The silence is confusing though.

[Mrragu]

To call NSPX a scam may be a little harsh. However, it definitely can be classified as a virtual company with no physical assets other than patents, Intellectual property, a rented office, a board of directors and at present time no CEO or way of communicating with anyone (like it is possible to find anyone) about the company. All company functions are out sourced. For years Sabby has financed all the cash expenditures from the company thru loans (convertible debentures) and have taken millions out of the company by converting debentures to stock and selling the stock on the OTC open market. Most of the actual INVESTORS in the company are penny stock traders looking to profit from advancement in stock PPS. Going forward, IF RT-AR001 gets the approval to start trials from the FDA that would give NSPX 2 sanctioned drugs (mipsagargin) in a cancer portfolio which may induce some investment or company sale. Other than Mipsagargin and RT-AR001 there has been no indication that other drugs are in the pipeline.

[WhaleEye]

I like that thinking.. :) Retire yes

[zino]

>>> Mipsagargin FDA Phase 2 Drug:

https://clinicaltrials.gov/ct2/results?term=Mipsagargin

>>> Mipsagargin Phase 2 Results: (Liver Cancer)

>>> Mipsagargin targeted approach differs from other vascular
targeting agents by destroying established tumor vasculature rather
than slowing the growth of new tumor blood vessels. The PSMA-targeting
agent is designed to minimize side effects commonly observed with other
therapies, while maximizing activity against tumors
https://www.prnewswire.com/news-releases/genspera-announces-positive-phase-ii-data-for-investigational-agent-mipsagargin-300021471.html

"Results demonstrate the potential that Mipsagargin has to treat one of
the world's deadliest cancers," said Devalingam Mahalingam, MD, PhD, an
oncologist at the Cancer Therapy & Research Center at the University of
Texas Health Science Center at San Antonio and principal investigator
of the study. "In addition to observing prolonged disease stabilization
in some patients, we noted anecdotal evidence that patients had
improved performance status with much less fatigue and side effects
associated with other anti-cancer therapeutics."
https://www.prnewswire.com/news-releases/genspera-announces-positive-phase-ii-data-for-investigational-agent-mipsagargin-300021471.html